Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Rang in aandelen #37499
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Aandeelprijs
$0.05897422
Laatst gesynchroniseerd: 2024-04-02
Marktkapitalisatie
$1.64M
Verandering (1 dag)
0.07%
Verandering (1 jaar)
-60.68%
Land
CA
Handel Intellipharmaceutics International Inc. (IPCI)

Categorie

Winst voor Intellipharmaceutics International Inc. (IPCI)
Winst in Aug 2023 TTM: $-3.17M
Volgens de meest recente financiële verslagen van Intellipharmaceutics International Inc. bedraagt de huidige winst van het bedrijf $-3.17M. In 2021 behaalde het bedrijf een winst van $-2.89M, een stijging ten opzichte van de winst van 2020, die $-5.26M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Intellipharmaceutics International Inc. van 1999 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-3.17M 9.75%
2022 $-2.89M 0.00%
2021 $-2.89M -45.11%
2020 $-5.26M 56.62%
2019 $-3.36M -75.57%
2018 $-13.75M 55.21%
2017 $-8.86M -12.68%
2016 $-10.14M 36.40%
2015 $-7.44M 92.83%
2014 $-3.86M -66.45%
2013 $-11.50M 135.54%
2012 $-4.88M 95.22%
2011 $-2.50M -56.34%
2010 $-5.73M -55.76%
2008 $-12.94M -56.95%
2007 $-30.07M -49.08%
2006 $-59.05M -25.61%
2005 $-79.37M 13.77%
2004 $-69.77M 173.92%
2003 $-25.47M 104.32%
2002 $-12.47M 36.27%
2001 $-9.15M 41.00%
2000 $-6.49M 0.00%
1999 0.00 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$5.27B -166,580.77%
US
$-3.09B 97,328.60%
US
$-4.02B 126,654.91%
AU
$1.95B -61,664.34%
NL
- -
CH